Oregon Hearing Research Center, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA.
Integr Biol (Camb). 2011 Sep;3(9):879-86. doi: 10.1039/c1ib00034a. Epub 2011 Jul 29.
Since introduction into clinical practice over 60 years ago, aminoglycoside antibiotics remain important drugs in the treatment of bacterial infections, cystic fibrosis and tuberculosis. However, the ototoxic and nephrotoxic properties of these drugs are still a major clinical problem. Recent advances in molecular biology and biochemistry have begun to uncover the intracellular actions of aminoglycosides that lead to cytotoxicity. In this review, we discuss intracellular binding targets of aminoglycosides, highlighting specific aminoglycoside-binding proteins (HSP73, calreticulin and CLIMP-63) and their potential for triggering caspases and Bcl-2 signalling cascades that are involved in aminoglycoside-induced cytotoxicity. We also discuss potential strategies to reduce aminoglycoside cytotoxicity, which are necessary for greater bactericidal efficacy during aminoglycoside pharmacotherapy.
自 60 多年前引入临床实践以来,氨基糖苷类抗生素仍然是治疗细菌感染、囊性纤维化和结核病的重要药物。然而,这些药物的耳毒性和肾毒性仍然是一个主要的临床问题。分子生物学和生物化学的最新进展开始揭示导致细胞毒性的氨基糖苷类药物的细胞内作用。在这篇综述中,我们讨论了氨基糖苷类药物的细胞内结合靶标,强调了特定的氨基糖苷类结合蛋白(HSP73、钙网蛋白和 CLIMP-63)及其触发半胱天冬酶和 Bcl-2 信号级联的潜力,这些级联参与了氨基糖苷类诱导的细胞毒性。我们还讨论了降低氨基糖苷类细胞毒性的潜在策略,这对于氨基糖苷类药物治疗期间提高杀菌效果是必要的。